Pharmablock Sciences(Nanjing)300725.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Pharmablock Sciences(Nanjing) (300725.SZ) trades at a P/E of 48.90x, P/B of 2.26x, P/S of 4.86x, and a dividend yield of 0.63%.
Longitudinal percentile comparison: P/E sits at the 42nd percentile over the trailing 10Y window (vs. 81st percentile over 3Y); P/B sits at the 18th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y); P/S sits at the 25th percentile over the trailing 10Y window (vs. 71st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 58th percentile within its industry and the 60th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.63%, ranking at the 71st percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 23.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Pharmablock Sciences(Nanjing) operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300725 · SZSE: 300725 · 300725
Want the full picture on whether Pharmablock Sciences(Nanjing) (300725.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 48.90 | ||||||
| P/B (MRQ) | 2.26 | ||||||
| P/S (TTM) | 4.86 | ||||||
| Dividend Yield | 0.63% | ||||||
| Buyback + Div Yield | 0.63% |